Reuman Michael, Beish Sandra, Davis Jeremy, Batchelor Mark J, Hutchings Martin C, Moffat David F C, Connolly Peter J, Russell Ronald K
Johnson and Johnson Pharmaceutical Research & Development, L.L.C., 1000 Route 202, Raritan, New Jersey 08869, USA.
J Org Chem. 2008 Feb 1;73(3):1121-3. doi: 10.1021/jo7021372. Epub 2008 Jan 3.
The preparation of the selective VEGF-R2 kinase inhibitor 10 (JNJ-17029259) is described in which the key precursor, 4-(5-isoxazolyl)benzonitrile, undergoes clean transformation to the corresponding cumylamine derivative with CeCl(3)-MeLi in THF. This high-yielding cerium mediated transformation is robust, reproducible, and readily scalable based on a requirement for the anhydrous CeCl(3) to be milled and subjected to ultrasound treatment prior to addition of methyllithium.